Cisplatin also reduced the number of MDSCs in bladder tumors by inhibiting methyltransferase 3 (METTL3)-mediated methylation of granulocyte colony-stimulating factor (G-CSF) [82]. Here, CSF3 is linked to urinary bladder neoplasm.